← All trials
NCT03740945
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2019
- Primary completion
- Mar 31, 2021
- Completion date
- Jun 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- EndoCeutics Inc.Lead sponsor
- AMAG Pharmaceuticals, Inc.Collaborator
- MacDonald Women's Hospital, ClevelandOverall official - principal investigator
- The Jones InstituteOverall official - principal investigator
- EndoCeutics Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.